Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Time to move toward a minimal residual disease-based definition of complete remission?

Journal of Clinical Oncology

Volumn 34, Issue 4, 2016, Pages 329-336

  Araki, Daisuke ^a   Wood, Brent L ^a   Othus, Megan ^b   Radich, Jerald P ^a,b   Halpern, Anna B ^a   Zhou, Yi ^a   Mielcarek, Marco ^a,b   Estey, Elihu H ^a,b   Appelbaum, Frederick R ^a,b   Walter, Roland B ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLOTRANSPLANTATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84955437697     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.3826     Document Type: Article

References (25)

1. Gupta V, Tallman MS, Weisdorf DJ: Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 117:2307-2318, 2011
2. Hamilton BK, Copelan EA: Concise review: The role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia. Stem Cells 30:1581-1586, 2012
3. Cornelissen JJ, Gratwohl A, Schlenk RF, et al: The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol 9:579-590, 2012
4. Kanate AS, Pasquini MC, Hari PN, et al: Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. World J Stem Cells 6:69-81, 2014
5. Vyas P, Appelbaum FR, Craddock C: Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 21:S3-S10, 2015 (suppl 2)
6. Buccisano F, Maurillo L, Del Principe MI, et al: Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119:332-341, 2012
7. Buckley SA, Appelbaum FR, Walter RB: Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant 48:630-641, 2013
8. Campana D, Leung W: Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation. Br J Haematol 162:147-161, 2013
9. Walter RB, Gooley TA, Wood BL, et al: Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 29:1190-1197, 2011
10. Walter RB, Buckley SA, Pagel JM, et al: Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122:1813-1821, 2013
11. Walter RB, Gyurkocza B, Storer BE, et al: Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia 29:137-144, 2015
12. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
13. Grimwade D, Hills RK, Moorman AV, et al: National Cancer Research Institute Adult Leukaemia Working Group: Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
14. Cheson BD, Bennett JM, Kopecky KJ, et al: International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649, 2003
15. Döhner H, Estey EH, Amadori S, et al: European LeukemiaNet: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
16. Przepiorka D, Weisdorf D, Martin P, et al: 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828, 1995
17. Filipovich AH, Weisdorf D, Pavletic S, et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945-956, 2005
18. Zhu HH, Zhang XH, Qin YZ, et al: MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: Results from the AML05 multicenter trial. Blood 121:4056-4062, 2013
19. Qin YZ, Xu LP, Chen H, et al: Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leuk Lymphoma 1-8, 2015
20. Kayser S, Schlenk RF, Grimwade D, et al: Minimal residual disease-directed therapy in acute myeloid leukemia. Blood 125:2331-2335, 2015
21. Freireich EJ, Gehan EA, Sulman D, et al: The effect of chemotherapy on acute leukemia in the human. J Chronic Dis 14:593-608, 1961
22. Walter RB, Kantarjian HM, Huang X, et al: Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center Study. J Clin Oncol 28:1766-1771, 2010
23. DiNardo CD, Luger SM: Beyond morphology: Minimal residual disease detection in acute myeloid leukemia. Curr Opin Hematol 19:82-88, 2012
24. Ravandi F, Jorgensen JL: Monitoring minimal residual disease in acute myeloid leukemia: Ready for prime time? J Natl Compr Canc Netw 10:1029-1036, 2012
25. Paietta E: Minimal residual disease in acute myeloid leukemia: Coming of age. Hematology (Am Soc Hematol Educ Program) 2012:35-42, 2012